Welcome to International Network for Natural Sciences | INNSpub

Methodological development of cytokine as a biomarker

Research Paper | December 1, 2016

| Download 4

Wardah Safdar, Maria Aftab, Beenish Saddique, Irsa Akhtar, Hamid Bashir, Muhammad Bilal, Aleena Sumrin

Key Words:

Int. J. Biosci.9( 6), 55-65, December 2016

DOI: http://dx.doi.org/10.12692/ijb/9.6.55-65


IJB 2016 [Generate Certificate]


Biomarker research has rapidly grown in the past few years owing mainly to the advanced development in research tools that provide simultaneous detection of a number of analytes in specific disease states. Cytokines are the polypeptide families released in inflammatory responses that control the immune system and their abnormal levels in the body can lead to multiple diseases. This review provides a detailed and systematic account of the steps in the development of cytokine biomarker. In this regard, serum or blood samples can be obtained from diseased persons and healthy individuals, wherein healthy samples can be regarded as reference standards. After processing according to standard procedures, relative quantitation of analytes can be performed by employing different assays like ELISA or advanced technologies like Luminex multiplex immunoassay and Mesoscale discovery. The statistical analysis can be performed with appropriate software’s like Bio-Plex Manager 5.0 and Master Plex QT software’s or simply with SPSS.  Subsequently, these assays can be validated according to the US Food and Drug Administration guidelines to verify the sensitivity and affinity of biomarker since the development parameters vary in every disease condition. Variations in cytokine levels can serve as a biomarker in certain ailments and careful experimentation paired with advanced technologies can be used for their exploitation.


Copyright © 2016
By Authors and International Network for
Natural Sciences (INNSPUB)
This article is published under the terms of the Creative
Commons Attribution Liscense 4.0

Methodological development of cytokine as a biomarker

Abbatiello SE, Mani D, Schilling B, MacLean B, Zimmerman LJ, Feng X, Cusack MP, Sedransk N, Hall SC, Addona T. 2013. Design, implementation and multisite evaluation of a system suitability protocol for the quantitative assessment of instrument performance in liquid chromatography-multiple reaction monitoring-MS (LC-MRM-MS). Molecular & Cellular Proteomics 12(9), 2623-2639.

Addona TA, Abbatiello SE, Schilling B, Skates SJ, Mani D, Bunk DM, Spiegelman CH, Zimmerman LJ, Ham A-JL, Keshishian H. 2009. Multi-site assessment of the precision and reproducibility of multiple reaction monitoring–based measurements of proteins in plasma. Nature biotechnology 27(7), 633-641.

Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G. 2006. Inflammation and cancer: how hot is the link? Biochemical pharmacology 72(11), 1605-1621.

Anbarasu D, Raja CP, Raja A. 2013. Multiplex analysis of cytokines/chemokines as biomarkers that differentiate healthy contacts from tuberculosis patients in high endemic settings. Cytokine 61(3), 747-754.

Ashwood P, Schauer J, Pessah IN, Van de Water J. 2009. Preliminary evidence of the in vitro effects of BDE-47 on innate immune responses in children with autism spectrum disorders. Journal of neuroimmunology 208(1), 130-135.

Aukrust P, Yndestad A, Smith C, Ueland T, Gullestad L, Damas JK. 2007. Chemokines in cardiovascular risk prediction. Thrombosis and Haemostasis Stuttgart 97(5), 748.

Bafadhel M, Saha S, Siva R, McCormick M, Monteiro W, Rugman P, Dodson P, Pavord ID, Newbold P, Brightling CE. 2009. Sputum IL-5 concentration is associated with a sputum eosinophilia and attenuated by corticosteroid therapy in COPD. Respiration 78(3), 256-262.

Bose M, Varma-Basil M, Jain A, Sethi T, Tiwari PK, Agrawal A, Banavaliker JN, Bhowmick KT. 2016. Establishment of Elevated Serum Levels of IL-10, IL-8 and TNF-[Beta] as Potential Peripheral Blood Biomarkers in Tubercular Lymphadenitis: A Prospective Observational Cohort Study. PloS one 11(1).

Britschgi M, Wyss-Coray T. 2009. Blood protein signature for the early diagnosis of Alzheimer disease. Archives of neurology 66(2), 161-165.

Burska A, Boissinot M, Ponchel F. 2014. Cytokines as biomarkers in rheumatoid arthritis. Mediators of inflammation 2014.

Charbonneau B, Maurer MJ, Ansell SM, Slager SL, Fredericksen ZS, Ziesmer SC, Macon WR, Habermann TM, Witzig TE, Link BK. 2012. Pretreatment circulating serum cytokines associated with follicular and diffuse large B-cell lymphoma: a clinic-based case-control study. Cytokine 60(3), 882-889.

Chen A, Oakley AE, Monteiro M, Tuomela K, Allan LM, Mukaetova-Ladinska EB, O’Brien JT, Kalaria RN. 2016. Multiplex analyte assays to characterize different dementias: brain inflammatory cytokines in poststroke and other dementias. Neurobiology of Aging 38, 56-67.

Chowdhury F, Williams A, Johnson P. 2009. Validation and comparison of two multiplex technologies, Luminex® and Mesoscale Discovery, for human cytokine profiling. Journal of immunological methods 340(1), 55-64.

Chun H-Y, Chung J-W, Kim H-A, Yun J-M, Jeon J-Y, Ye Y-M, Kim S-H, Park H-S, Suh C-H. 2007. Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus. Journal of clinical immunology 27(5), 461-466.

Cuellar JM, Scuderi GJ, Cuellar VG, Golish SR, Yeomans DC. 2009. Diagnostic utility of cytokine biomarkers in the evaluation of acute knee pain. J Bone Joint Surg Am 91(10), 2313-2320.

Dabitao D, Margolick JB, Lopez J, Bream JH. 2011. Multiplex measurement of proinflammatory cytokines in human serum: comparison of the Meso Scale Discovery electrochemiluminescence assay and the Cytometric Bead Array. Journal of immunological methods 372(1), 71-77.

Dancey JE, Dobbin KK, Groshen S, Jessup JM, Hruszkewycz AH, Koehler M, Parchment R, Ratain MJ, Shankar LK, Stadler WM. 2010. Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. Clinical Cancer Research 16(6), 1745-1755.

de Jager W, Bourcier K, Rijkers GT, Prakken BJ, Seyfert-Margolis V. 2009. Prerequisites for cytokine measurements in clinical trials with multiplex immunoassays. BMC immunology 10(1), 52.

de Jager W, Rijkers GT. 2006. Solid-phase and bead-based cytokine immunoassay: a comparison. Methods 38(4), 294-303.

Domanski D, Percy AJ, Yang J, Chambers AG, Hill JS, Freue GVC, Borchers CH. 2012. MRM‐based multiplexed quantitation of 67 putative cardiovascular disease biomarkers in human plasma. Proteomics 12(8), 1222-1243.

Duramad P, Tager IB, Holland NT. 2007. Cytokines and other immunological biomarkers in children’s environmental health studies. Toxicology letters 172, 48-59.

Elshal MF, McCoy JP. 2006. Multiplex bead array assays: performance evaluation and comparison of sensitivity to ELISA. Methods 38(4), 317-323.

Farrah T, Deutsch EW, Omenn GS, Campbell DS, Sun Z, Bletz JA, Mallick P, Katz JE, Malmström J, Ossola R. 2011. A high-confidence human plasma proteome reference set with estimated concentrations in PeptideAtlas. Molecular & Cellular Proteomics 10(9), M110. 006353.

Food, Administration D. 2007. Guidance for industry: bioanalytical method validation (2001). Available from: www​ fda​ gov/​downloads/​drugs/​ guidancecomplian​ ceregulatoryinfo​ rmation/​ guidances/​ ucm368107​ pdf.

GarciaZepeda E, RojasLopez A, EsquivelVelazquez M, OstoaSaloma P. 2007. Regulation of the inflammatory immune response by the cytokine/chemokine network in amoebiasis. Parasite immunology 29(12), 679-684.

Goldberg RB. 2009. Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. The Journal of Clinical Endocrinology & Metabolism 94(9), 3171-3182.

Haab BB, Paulovich AG, Anderson NL, Clark AM, Downing GJ, Hermjakob H, LaBaer J, Uhlen M. 2006. A Reagent Resource to Identify Proteins and Peptides of Interest for the Cancer Community A Workshop Report. Molecular & Cellular Proteomics 5(10), 1996-2007.

Holland NT, Pfleger L, Berger E, Ho A, Bastaki M. 2005. Molecular epidemiology biomarkers—sample collection and processing considerations. Toxicology and applied pharmacology 206(2), 261-268.

Hu S, Loo JA, Wong DT. 2006. Human body fluid proteome analysis. Proteomics 6(23), 6326-6353.

Huang R-P, Burkholder B, Sloane Jones V, Jiang W-D, Mao Y-Q, Chen Q-L, Shi Z. 2012. Cytokine antibody arrays in biomarker discovery and validation. Current Proteomics 9(1), 55-70.

Keustermans GC, Hoeks SB, Meerding JM, Prakken BJ, de Jager W. 2013. Cytokine assays: an assessment of the preparation and treatment of blood and tissue samples. Methods 61(1), 10-17.

Khan IH, Krishnan V, Ziman M, Janatpour K, Wun T, Luciw PA, Tuscano J. 2009. A comparison of multiplex suspension array large‐panel kits for profiling cytokines and chemokines in rheumatoid arthritis patients. Cytometry Part B: Clinical Cytometry 76(3), 159-168.

Kofoed K, Schneider UV, Scheel T, Andersen O, Eugen-Olsen J. 2006. Development and validation of a multiplex add-on assay for sepsis biomarkers using xMAP technology. Clinical chemistry 52(7), 1284-1293.

Krastins B, Prakash A, Sarracino DA, Nedelkov D, Niederkofler EE, Kiernan UA, Nelson R, Vogelsang MS, Vadali G, Garces A. 2013. Rapid development of sensitive, high-throughput, quantitative and highly selective mass spectrometric targeted immunoassays for clinically important proteins in human plasma and serum. Clinical biochemistry 46(6), 399-410.

Ledger KS, Agee SJ, Kasaian MT, Forlow SB, Durn BL, Minyard J, Lu QA, Todd J, Vesterqvist O, Burczynski ME. 2009. Analytical validation of a highly sensitive microparticle-based immunoassay for the quantitation of IL-13 in human serum using the Erenna® immunoassay system. Journal of immunological methods 350(1), 161-170.

Lee JW, Devanarayan V, Barrett YC, Weiner R, Allinson J, Fountain S, Keller S, Weinryb I, Green M, Duan L. 2006. Fit-for-purpose method development and validation for successful biomarker measurement. Pharmaceutical research 23(2), 312-328.

Leng SX, McElhaney JE, Walston JD, Xie D, Fedarko NS, Kuchel GA. 2008. ELISA and multiplex technologies for cytokine measurement in inflammation and aging research. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 63(8), 879-884.

Linkov F, Ferris RL, Yurkovetsky Z, Marrangoni A, Velikokhatnaya L, Gooding W, Nolan B, Winans M, Siegel ER, Lokshin A. 2008. Multiplex analysis of cytokines as biomarkers that differentiate benign and malignant thyroid diseases. Proteomics-Clinical Applications 2(12), 1575-1585.

Maier B, Lefering R, Lehnert M, Laurer HL, Steudel WI, Neugebauer EA, Marzi I. 2007. Early versus late onset of multiple organ failure is associated with differing patterns of plasma cytokine biomarker expression and outcome after severe trauma. Shock 28(6), 668-674.

Metcalf SW, Orloff KG. 2004. Biomarkers of exposure in community settings. Journal of Toxicology and Environmental Health, Part A 67(8-10), 715-726.

Miller M, Cho JY, Pham A, Ramsdell J, Broide DH. 2009. Adiponectin and functional adiponectin receptor 1 are expressed by airway epithelial cells in chronic obstructive pulmonary disease. The Journal of Immunology 182(1), 684-691.

Mire-Sluis AR, Barrett YC, Devanarayan V, Koren E, Liu H, Maia M, Parish T, Scott G, Shankar G, Shores E. 2004. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. Journal of immunological methods 289(1), 1-16.

Mueller SC, März R, Schmolz M, Drewelow B. 2012. Intraindividual long term stability and response corridors of cytokines in healthy volunteers detected by a standardized whole-blood culture system for bed-side application. BMC medical research methodology 12(1), 112.

Othman EE-DR, Hornung D, Salem HT, Khalifa EA, El-Metwally TH, Al-Hendy A. 2008. Serum cytokines as biomarkers for nonsurgical prediction of endometriosis. European Journal of Obstetrics & Gynecology and Reproductive Biology 137(2), 240-246.

Paczesny S, Krijanovski OI, Braun TM, Choi SW, Clouthier SG, Kuick R, Misek DE, Cooke KR, Kitko CL, Weyand A. 2009. A biomarker panel for acute graft-versus-host disease. Blood 113(2), 273-278.

Panicker G, Meadows KS, Lee DR, Nisenbaum R, Unger ER. 2007. Effect of storage temperatures on the stability of cytokines in cervical mucous. Cytokine 37(2), 176-179.

Parker CE, Pearson TW, Anderson NL, Borchers CH. 2010. Mass-spectrometry-based clinical proteomics–a review and prospective. Analyst 135(8), 1830-1838.

Paulovich AG, Billheimer D, Ham A-JL, Vega-Montoto L, Rudnick PA, Tabb DL, Wang P, Blackman RK, Bunk DM, Cardasis HL. 2010. Interlaboratory study characterizing a yeast performance standard for benchmarking LC-MS platform performance. Molecular & Cellular Proteomics 9(2), 242-254.

Penna G, Mondaini N, Amuchastegui S, Degli Innocenti S, Carini M, Giubilei G, Fibbi B, Colli E, Maggi M, Adorini L. 2007. Seminal plasma cytokines and chemokines in prostate inflammation: interleukin 8 as a predictive biomarker in chronic prostatitis/chronic pelvic pain syndrome and benign prostatic hyperplasia. European urology 51(2), 524-533.

Percy AJ, Chambers AG, Yang J, Hardie DB, Borchers CH. 2014. Advances in multiplexed MRM-based protein biomarker quantitation toward clinical utility. Biochimica et Biophysica Acta (BBA)-Proteins and Proteomics 1844(5), 917-926.

Pokkali S, Das SD. 2009. Augmented chemokine levels and chemokine receptor expression on immune cells during pulmonary tuberculosis. Human immunology 70(2), 110-115.

Rang HP, Dale MM, Ritter JM, Flower RJ, Henderson G. 2011. Rang & Dale’s Pharmacology: Elsevier Health Sciences UK.

Richens JL, Urbanowicz RA, Metcalf R, Corne J, O’Shea P, Fairclough L. 2010. Quantitative validation and comparison of multiplex cytokine kits. Journal of biomolecular screening 15(5), 562-568.

Ryu M-S, Langkamp-Henken B, Chang S-M, Shankar MN, Cousins RJ. 2011. Genomic analysis, cytokine expression, and microRNA profiling reveal biomarkers of human dietary zinc depletion and homeostasis. Proceedings of the National Academy of Sciences 108(52), 20970-20975.

Shafer MW, Mangold L, Partin AW, Haab BB. 2007. Antibody array profiling reveals serum TSP‐1 as a marker to distinguish benign from malignant prostatic disease. The Prostate 67(3), 255-267.

Shaw VE, Lane B, Jenkinson C, Cox T, Greenhalf W, Halloran CM, Tang J, Sutton R, Neoptolemos JP, Costello E. 2014. Serum cytokine biomarker panels for discriminating pancreatic cancer from benign pancreatic disease. Molecular cancer 13(1), 1. 

Srivastava M, Eidelman O, Jozwik C, Paweletz C, Huang W, Zeitlin PL, Pollard HB. 2006. Serum proteomic signature for cystic fibrosis using an antibody microarray platform. Molecular genetics and metabolism 87(4), 303-310.

Toedter G, Hayden K, Wagner C, Brodmerkel C. 2008. Simultaneous detection of eight analytes in human serum by two commercially available platforms for multiplex cytokine analysis. Clinical and Vaccine Immunology 15(1), 42-48.

van Bon L, Affandi AJ, Broen J, Christmann RB, Marijnissen RJ, Stawski L, Farina GA, Stifano G, Mathes AL, Cossu M. 2014. Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. New England Journal of Medicine 370(5), 433-443.

Wang K, Wadhwa PD, Culhane JF, Nelson EL. 2005. Validation and comparison of luminex multiplex cytokine analysis kits with ELISA: determinations of a panel of nine cytokines in clinical sample culture supernatants. Journal of reproductive immunology 66(2), 175-191.

Wang P, Whiteaker JR, Paulovich AG. 2009. The evolving role of mass spectrometry in cancer biomarker discovery. Cancer biology & therapy 8(12), 1083-1094.

Zhu CS, Pinsky PF, Cramer DW, Ransohoff DF, Hartge P, Pfeiffer RM, Urban N, Mor G, Bast RC, Moore LE. 2011. A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer. Cancer Prevention Research 4(3), 375-383.